Literature DB >> 26557579

Current Clinical Practice Scenario of Osteoporosis Management in India.

Shailesh Jhaveri1, Tejas Upashani2, Jitendra Bhadauria3, Swati Biswas3, Kamlesh Patel4.   

Abstract

BACKGROUND: Various osteoporosis guidelines are available for practice. AIM: To understand the current clinical practice scenario from the perspective of Indian orthopaedicians, especially about the epidemiology, clinical manifestations, approach to diagnosis and management and patient compliance patterns to long term treatment.
MATERIALS AND METHODS: A pre-validated structured questionnaire containing questions (mostly objective, some open-ended) catering to various objectives of the study was circulated amongst orthopaedic surgeons across India by means of post/courier, after giving a brief overview of the study telephonically. Data was extracted from the completed questionnaires, and analysed using Microsoft Excel software.
RESULTS: The questionnaire was filled by a total of 84 orthopaedicians throughout India. The prevalence of osteoporosis in India according to the orthopaedic surgeons was 38.4% and there was a female preponderance. Most of the respondents felt out of every 100 osteoporosis patients in India, less than 20 patients are actually diagnosed and treated for osteoporosis. The most common initial presenting feature of established osteoporosis cases was general symptoms. Most respondents preferred Dual-energy X-ray absorptiometry (DEXA) as the initial investigation for the diagnosis of osteoporosis in a patient presenting with typical features. While most respondents preferred once-a-month oral over intravenous (IV) bisphosphonates, they agreed that IV administration had advantages such as lower gastrointestinal side effects and improved compliance. The average duration of therapy of oral bisphosphonates was the longest (27.04 months) among the other anti- osteoporosis therapies that they used. On an average, the patient compliance rate in osteoporosis management was around 64%. IV Zoledronic acid (ZA) and intranasal calcitonin were infrequently used than other anti- osteoporosis therapies. While concerns about cost and availability deterred more frequent usage, there was an agreement that if used regularly these two agents may improve compliance rates among patients.
CONCLUSION: Current clinical practice scenario of osteoporosis management in India largely adheres to various clinical practice guidelines for osteoporosis. Side effects and lengthy duration of therapy with bisphosphonates seem to be the main factors leading to a low patient compliance. Widespread popularization of once-yearly Zoledronic acid and intranasal calcitonin spray may improve patient compliance and reduce side effect incidence.

Entities:  

Keywords:  Bisphosphonates; Calcitonin; Compliance; Osteoporosis; Zoledronate

Year:  2015        PMID: 26557579      PMCID: PMC4625298          DOI: 10.7860/JCDR/2015/13000.6635

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  10 in total

Review 1.  Biochemical markers in osteoporosis: usefulness in clinical practice.

Authors:  Carmen M Romero Barco; Sara Manrique Arija; Manuel Rodríguez Pérez
Journal:  Reumatol Clin       Date:  2011-09-08

2.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

Authors:  Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak
Journal:  Endocr Pract       Date:  2010 Nov-Dec       Impact factor: 3.443

Review 3.  Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis.

Authors:  K Ganda; M Puech; J S Chen; R Speerin; J Bleasel; J R Center; J A Eisman; L March; M J Seibel
Journal:  Osteoporos Int       Date:  2012-07-25       Impact factor: 4.507

Review 4.  A systematic review of persistence and compliance with bisphosphonates for osteoporosis.

Authors:  J A Cramer; D T Gold; S L Silverman; E M Lewiecki
Journal:  Osteoporos Int       Date:  2007-02-17       Impact factor: 4.507

Review 5.  Calcitonin therapy in osteoporosis.

Authors:  Manuel Muñoz-Torres; Guillermo Alonso; Mezquita Pedro Raya
Journal:  Treat Endocrinol       Date:  2004

6.  Prevalence of osteoporosis in otherwise healthy Indian males aged 50 years and above.

Authors:  Neeraj Kumar Agrawal; Balram Sharma
Journal:  Arch Osteoporos       Date:  2013-02-01       Impact factor: 2.617

7.  Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians.

Authors:  Amir Qaseem; Vincenza Snow; Paul Shekelle; Robert Hopkins; Mary Ann Forciea; Douglas K Owens
Journal:  Ann Intern Med       Date:  2008-09-16       Impact factor: 25.391

8.  Intravenous bisphosphonates for postmenopausal osteoporosis.

Authors:  Peyman Mottaghi
Journal:  J Res Med Sci       Date:  2010-05       Impact factor: 1.852

9.  Prevalence and related risk factors of osteoporosis in peri- and postmenopausal Indian women.

Authors:  Neelam Aggarwal; Ainharan Raveendran; Niranjan Khandelwal; Ramesh Kumar Sen; J S Thakur; Lakhbir Kaur Dhaliwal; Veenu Singla; Sakthivel Rajan Rajaram Manoharan
Journal:  J Midlife Health       Date:  2011-07

10.  Effective risk assessment tools for osteoporosis in the Indian menopausal female.

Authors:  Seema Sharma; Sunila Khandelwal
Journal:  J Midlife Health       Date:  2010-07
  10 in total
  2 in total

1.  ClC-3 chloride channel mediates the role of parathyroid hormone [1-34] on osteogenic differentiation of osteoblasts.

Authors:  Xiaolin Lu; Yin Ding; Qiannan Niu; Shijie Xuan; Yan Yang; Yulong Jin; Huan Wang
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240

2.  The Indian Society for Bone and Mineral Research (ISBMR) position statement for the diagnosis and treatment of osteoporosis in adults.

Authors:  Sanjay K Bhadada; Manoj Chadha; Usha Sriram; Rimesh Pal; Thomas V Paul; Rajesh Khadgawat; Ameya Joshi; Beena Bansal; Nitin Kapoor; Anshita Aggarwal; Mahendra K Garg; Nikhil Tandon; Sushil Gupta; Narendra Kotwal; Shriraam Mahadevan; Satinath Mukhopadhyay; Soham Mukherjee; Subhash C Kukreja; Sudhaker D Rao; Ambrish Mithal
Journal:  Arch Osteoporos       Date:  2021-06-26       Impact factor: 2.617

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.